{"disease":{"id":"neuroendocrine-carcinoma-of-the-bladder","name":"neuroendocrine carcinoma of the bladder"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03992911","title":"Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":336,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT06091124","title":"Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"RenJi Hospital","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}